Prevalence of non alcoholic Fatty Liver Disease (NAFLD) Diagnosed by Ultrasound Abdomen and its Association with Insulin Resistance Measured by HOMA-IR.
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 80
- Locations
- 1
Study Overview
Brief Summary
Non-alcoholic fatty liver disease (NAFLD) is emerging as a major public health problem, closely linked with obesity, insulin resistance, and type 2 diabetes. Early identification of patients at risk is essential to prevent progression to steatohepatitis, fibrosis, and cirrhosis. This cross-sectional study evaluates the prevalence of NAFLD diagnosed by abdominal ultrasonography and examines its association with insulin resistance measured using the HOMA IR index. Adults aged 18 to 65 years with ultrasound-confirmed fatty liver (Grades I to III) and available fasting glucose and insulin values are enrolled. Anthropometry and relevant clinical data are recorded. Correlation between HOMA IR and ultrasound grading is analyzed using Spearmans correlation, with additional comparisons across grades. Secondary analyses explore relationships with BMI and waist circumference. The study aims to determine whether higher HOMA IR values predict more severe fatty liver, thereby supporting HOMA IR as a simple, affordable surrogate marker to complement imaging and guide early intervention in resource limited settings.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18.00 Year(s) to 65.00 Year(s) (—)
- Sex
- All
Inclusion Criteria
- •Patients diagnosed with fatty liver on ultrasound ,Grades I to III Patients who have undergone fasting blood glucose and fasting insulin testing for HOMA IR calculation.
- •Patients who consent to participate in the study.
- •Patients with Type 2 Diabetes Mellitus.
Exclusion Criteria
- •1 Known cases of Type 1 Diabetes Mellitus.
- •2 Patients on medications affecting insulin sensitivity (example glucocorticoids, metformin).
- •3 Significant alcohol intake (more than 20 g per day in females, more than 30 g perday in males).
- •4 Patients with chronic liver diseases other than fatty liver (e.g., viral hepatitis, autoimmune hepatitis, Wilsons disease).
- •5 Pregnant or lactating women.
- •6 Critically ill or hospitalised patients with acute systemic illness.
Investigators
Dr Anupam Aji
Vinayaka Missions Kirupananda Variyar Medical College And Hospitals, Salem